IPCA Laboratories Limited announced the outcome of its Board Meeting held on January 13, 2026. The Board approved the sale of 100% shareholding of its wholly-owned step-down subsidiary, Bayshore Pharmaceuticals LLC, USA, to Centaur Pharmaceuticals USA Inc. for USD 4,00,000 (USD four lacs only). This transaction follows the earlier sale of Bayshore's product approvals and business operations in the USA to Unichem Laboratories Ltd. and Unichem Pharmaceuticals (USA) Inc. respectively, in September 2024. Post these transactions, Bayshore was not conducting any business and had no assets or liabilities, except for its share capital and a small bank balance. The sale to Centaur Pharmaceuticals USA Inc. is subject to necessary due diligence and approvals.

The company also proposed to update its registered office address to include the district details. Currently, the Ministry of Corporate Affairs (MCA) master data does not include 'Mumbai' as the district for the registered office, preventing the company from filing online Industrial Entrepreneur Memorandum (IEM) applications for new industrial projects. A new online Form INC-22 will be filed to incorporate the district detail, although there is no change in the physical registered office address. The Board meeting commenced at 10:15 am and concluded at 10:35 am on January 13, 2026.